全球癌症治療市場新型藥物輸送系統研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

全球癌症治療市場對新型藥物輸送系統的需求預計將從 2022 年的 144.8 億美元增至 2030 年的近 853.2 億美元，2023-2030 年研究期間CAGR為 24.82%。

癌症治療中的新型藥物輸送系統旨在以相對於身體其他部位增加特定部位藥物濃度的方式輸送藥物。新型藥物輸送系統 (NDDS) 透過減少給藥頻率提供更好的患者依從性。 NDDS對於癌症治療具有顯著的優勢，包括提高溶解度和生物利用度、降低毒性、最大治療效果、持續和受控的藥物輸送、提高穩定性以及更好的物理和生化分解安全性。

市場動態：

由於癌症治療的巨大益處，全球新型藥物傳輸系統在癌症治療市場上可能會擴大。此外，新型藥物輸送系統市場主要受到癌症發生率上升的影響。此外，開發新型藥物傳輸技術的研究活動增加，同時對正在進行的研究計畫的資助也有所增加。此外，用於癌症診斷和治療的醫療保健支出的增加可能會推動 NDDS 市場的成長。然而，高昂的治療成本可能會限制市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球癌症治療新型藥物傳輸系統市場的各個細分市場進行了包容性評估。癌症治療產業中新型藥物輸送系統的成長和趨勢為這項研究提供了整體方法。

區域分析：

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲癌症治療市場中新型藥物輸送系統當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。癌症治療市場新藥物輸送系統的主要參與者包括 Teva Pharmaceutical Industries Ltd.、Johnson & Johnson Services, Inc.、GALEN、Merrimack Pharmaceuticals Inc.、Shire、Samyang Biopharmaceuticals Corporation、Celgene Corporation、Spectrum Pharmaceuticals Inc.、BTG 。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第 1 章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：癌症治療中的新型藥物輸送系統 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按產品分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：COVID-19 爆發的影響分析

第 6 章：癌症治療市場中的全球新型藥物輸送系統分析：依產品

• 按產品概述
• 歷史和預測數據
• 按產品分析
• 奈米顆粒（脂質體、聚合物、膠束、其他奈米顆粒）
• 栓塞顆粒（PVA顆粒、藥物洗脫珠、液體栓塞、其他栓塞顆粒）

第 7 章：癌症治療市場中的全球新型藥物輸送系統分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概述、歷史和預測銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概述、歷史和預測銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概述、歷史和預測銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概述、歷史和預測銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概述、歷史和預測銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：癌症治療公司新型藥物輸送系統的競爭格局

• 癌症治療市場競爭中的新型藥物傳輸系統
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Teva Pharmaceutical Industries Ltd.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Johnson & Johnson Services Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• GALEN
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Merrimack Pharmaceuticals Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Shire
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Samyang Biopharmaceuticals Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Celgene Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Spectrum Pharmaceuticals Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• BTG
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Novel Drug Delivery Systems in Cancer Therapy Market is presumed to reach the market size of nearly USD 85.32 BN by 2030 from USD 14.48 BN in 2022 with a CAGR of 24.82% under the study period 2023 - 2030.

Novel drug delivery systems in cancer therapy aim to deliver medication in a manner that increases its concentration at a specific site relative to other parts of the body. A novel drug delivery system (NDDS) offers better patient compliance via the diminished frequency of dose. NDDS have significant advantages for cancer treatment, including improved solubility and bioavailability, reduced toxicity, maximum therapeutic effect, sustained and controlled drug delivery, increased stability and better security against physical and biochemical degradation.

MARKET DYNAMICS:

The global novel drug delivery systems in the cancer therapy market are likely to expand due to substantial benefits for cancer treatment. Also, the novel drug delivery systems market is mainly influenced by a rise in the incidences of cancer. Moreover, rise in research activities for the development of technologies of novel drug delivery coupled with augmented funding for ongoing research projects. Furthermore, a rise in healthcare expenditure for the diagnosis and treatment of cancer is likely to propel the NDDS market growth. However, the high cost of therapy may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of novel drug delivery systems in cancer therapy. The growth and trends of novel drug delivery systems in cancer therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the novel drug delivery systems in cancer therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Nanoparticles (Liposomes, Polymers, Micelles, Other Nanoparticles)
• Embolization Particles (Pva Particles, Drug-Eluting Beads, Liquid Emboli, Other Embolization Particles)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Novel Drug Delivery Systems in Cancer Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the novel drug delivery systems in cancer therapy market include Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals Inc., Shire, Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals Inc., BTG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY PRODUCT

• 6.1 Overview by Product
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product
• 6.4 Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Historic and Forecast Sales by Regions
• 6.5 Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Historic and Forecast Sales by Regions

7 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY COMPANIES

• 8.1. Novel Drug Delivery Systems In Cancer Therapy Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Teva Pharmaceutical Industries Ltd.
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Johnson & Johnson Services Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. GALEN
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Merrimack Pharmaceuticals Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Shire
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Samyang Biopharmaceuticals Corporation
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Celgene Corporation
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Spectrum Pharmaceuticals Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. BTG
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Market Sales by Geography (USD MN)
• Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Market Sales by Geography (USD MN)
• Global Novel Drug Delivery Systems In Cancer Therapy Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Novel Drug Delivery Systems In Cancer Therapy Report
• Market Research Process
• Market Research Methodology
• Global Novel Drug Delivery Systems In Cancer Therapy Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Market Sales by Geography (USD MN)
• Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.